Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 10/20 | 0.39 |
| ▸ | NPC1 | O15118 | 8/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358579 | 0.87 | L3MBTL1 (0.53) | MTORABL1NNMTRAB9ANPC1 | |
| SCHEMBL2731655 | 0.83 | CNR2 (0.51) | MTORABL1NNMTRAB9ANPC1 | |
| SCHEMBL30207707 | 0.83 | CNR2 (0.51) | MTORABL1NNMTRAB9ANPC1 | |
| SCHEMBL3466797 | 0.82 | NNMT (0.44) | NNMTRAB9ANPC1TP53KMT2A | |
| SCHEMBL7936580 | 0.82 | ABL1 (0.43) | MTORABL1RAB9AKMT2AMEN1 | |
| SCHEMBL16905389 | 0.79 | GSK3B (0.46) | MTORABL1MAPK1 | |
| SCHEMBL30107231 | 0.79 | GSK3B (0.46) | MTORABL1MAPK1 | |
| SCHEMBL15890212 | 0.79 | KMT2A (0.48) | MTORABL1TP53MAPK1KMT2A | |
| SCHEMBL17912921 | 0.78 | NPC1 (0.46) | ABL1RAB9ANPC1MAPK1ALDH1A1 | |
| SCHEMBL31241121 | 0.78 | RAB9A (0.62) | RAB9ANPC1MAPK1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| EP-3941908-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3768269-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020198026-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2019183587-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2010072722-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | MTOR 1849/4885ABL1 1051/4885NNMT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.